Gulf Resources Secures Approval to Restart Two Bromine Factories, but Distress Persists

What happened

Gulf Resources announced on October 14, 2026 that it received approval from the Shouguang Municipal Government to resume production at its Factories No. 2 and No. 10. This regulatory green light comes amid severe operational and financial deterioration: revenue fell from $66.1 million in 2022 to $7.7 million in 2024, while net income swung from a $10.1 million profit to losses of $61.8 million and $58.9 million over the same period. Cash has collapsed from roughly $108 million in 2022 to $5.8 million by the end of September 2025, and equity has shrunk from $271.6 million to $107.5 million in less than three years, with the stock now trading over-the-counter at a micro-cap valuation. The company's bromine capacity was running at only about 20% utilization in the first nine months of 2025, and chemical and natural gas segments generated no revenue, so restarting these two factories may help but is unlikely to reverse the underlying distress without a sustained improvement in volumes and margins. Given the history of governance concerns, large impairments, and regulatory shutdowns, this approval should be viewed as a modest positive checkpoint rather than a fundamental turning point.

Implication

The resumption of two bromine factories may slightly improve near-term revenue and reduce fixed cost burdens, but the company's overall capacity utilization remains extremely low and its chemical and natural gas segments are dormant. With cash at only $5.8 million as of September 2025 and continued losses, the company faces a high risk of liquidity distress or dilutive financing even if production resumes. Regulatory approvals carry execution risk: past shutdowns and compliance costs have repeatedly disrupted operations, and future environmental enforcement could again halt production. Investors should monitor quarterly bromine volumes, gross margins, and operating cash flow for evidence that the restart leads to sustainable profitability rather than a one-off regulatory reprieve. Until such evidence appears, the valuation remains a speculative deep-value option with limited downside protection and a high probability of permanent capital loss, consistent with the strong sell judgment.

Thesis delta

The approval to resume production at Factories No. 2 and No. 10 is a modest positive catalyst that addresses one of the company's operational bottlenecks. However, it does not change the core thesis of severe value destruction, inadequate liquidity, and high governance risk. The strong sell stance remains intact unless the restart leads to a sustained increase in utilization, revenue, and cash flow.